The FDA's approval of Intuniv brings to four the number of drugs for ADHD currently marketed by Shire. (The other three are Adderall XR, Vyvanse and the Daytrana patch.) There are about 11 drugs on ...

Intuniv is available as 1mg, 2mg, 3mg, and 4mg extended-release tablets The Food and Drug Administration (FDA) has approved a new update to the Intuniv (guanfacine; Shire) labeling regarding ...

INTUNIV (guanfacine) 1mg, 2mg, 3mg, 4mg ext-rel tablets by Shire The FDA has approved once-daily Intuniv (guanfacine extended-release tablets, from Shire), a selective alpha-2A adrenergic receptor ...

Data from a Phase III study evaluating Shire’s Intuniv in Japan in adults with attention deficit hyperactivity disorder indicate that the drug could improve symptoms of the condition in this patient ...

"The approval of INTUNIV marks a significant advance in the treatment of ADHD in children and adolescents in Europe. Previously, physicians had only one licensed non-stimulant option for these ...

Teva Pharmaceutical Industries Ltd is seeking to disqualify two expert witnesses hired by plaintiffs who are accusing one of the drugmaker's units of illegally delaying the release of a generic ...

Days after announcing plans to sue Teva Pharmaceutical Industries over patent infringement of Intuniv, Shire has been informed that another company is hoping to launch its generic version of the ...

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that it has received an approvable letter from the US Food and Drug Administration (FDA) for INTUNIV (guanfacine) extended Shire announced ...

WASHINGTON, May 7 -- Shire plc(LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented today at a major scientific meeting findings from analyses of pivotal trial results ...